

Product Information

Size:

50ul

Reactivity:

Human, Mouse

Source:

Rabbit

Isotype:

IgG

Applications:

ELISA, WB, IHC

Recommended dilutions:

ELISA:1:1000-1:2000, WB:1:200-1:1000,
IHC:1:50-1:200

Protein Background:

Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFBR1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes.

Gene ID:

IPO9

Uniprot

Q96P70

Synonyms:

importin 9


Immunogen:

Synthetic peptide of human IPO9.


Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol


Product Images



The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO19843(IPO9 Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: x—200).



Gel: 6%SDS-PAGE, Lysate: 40 μ g, Lane 1-2: Human fetal brain tissue, Hela cells, Primary antibody: PACO19843(IPO9 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute.



The image on the left is immunohistochemistry of paraffin-embedded Human colon cancer tissue using PACO19843(IPO9 Antibody) at dilution 1/20, on the right is treated with synthetic peptide. (Original magnification: x—200).